Breast Cancer, HR+/HER2- Early-Stage
1 clinical trials · Condition
◉ Watch Breast Cancer, HR+/HER2- Early-Stage
| Record | Firm | Date |
|---|---|---|
| Predicting Recurrence in HR+/HER2- Early Breast Cancer (NCT07484763) | Shengjing Hospital | 2026-04-01 |
Track Breast Cancer, HR+/HER2- Early-Stage automatically
Every clearance here is in the API, with alerts when new ones post.